Prime Medicine (PRME) Cash from Investing Activities (2021 - 2026)

Prime Medicine's Cash from Investing Activities history runs 6 years deep, the most recent figure standing at $43.4 million for Q1 2026.

• Quarterly Cash from Investing Activities rose 190.89% year-over-year to $43.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$17.6 million (down 130.53% YoY) and the FY2025 annual result came in at -$108.8 million, down 258.88% from the prior year.
• Cash from Investing Activities was $43.4 million for Q1 2026 at Prime Medicine, up from $28.3 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $50.3 million in Q3 2024 and bottomed at -$92.1 million in Q3 2025.
• A 5-year average of -$1.5 million and a median of $2.8 million in 2025 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities jumped 401.64% — and 2025, when it plunged 282.99%.
• Prime Medicine's Cash from Investing Activities stood at -$13.7 million in 2022, then soared by 401.64% to $41.3 million in 2023, then rose by 16.88% to $48.3 million in 2024, then plunged by 41.29% to $28.3 million in 2025, then soared by 53.16% to $43.4 million in 2026.
• Business Quant data shows PRME's Cash from Investing Activities at $43.4 million in Q1 2026, $28.3 million in Q4 2025, and -$92.1 million in Q3 2025.